Isoform level expression profiles provide better cancer signatures than gene level expression profiles

Genome Medicine

Volumn 5, Issue 4, 2013, Pages

  Zhang, ZhongFa ^a   Pal, Sharmistha ^a   Bi, Yingtao ^a   Tchou, Julia ^b   Davuluri, Ramana V ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BREAST CANCER; DOWN REGULATION; EXON; GENE CLUSTER; GENE LEVEL EXPRESSION; GENE MAPPING; GENETIC PARAMETERS; HUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PURINE METABOLISM; UBIQUITINATION; UPREGULATION;

EID: 84876093812     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm437     Document Type: Article

References (53)

1. Heard E, Tishkoff S, Todd JA, Vidal M, Wagner GP, Wang J, Weigel D, Young R. Ten years of genetics and genomics: what have we achieved and where are we heading?. Nat Rev Genet 2010, 11:723-733. 10.1038/nrg2878, 3004366, 20820184.
2. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 2010, 13:297-309. 3068535, 20443163.
3. Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol Biosyst 2009, 5:1536-1548. 10.1039/b908147j, 19763339.
4. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009, 100:1517-1522. 10.1038/sj.bjc.6605031, 2696770, 19367275.
5. Feero WG, Guttmacher AE, Collins FS. Genomic medicine--an updated primer. The New England journal of medicine 2010, 362:2001-2011. 10.1056/NEJMra0907175, 20505179.
6. Gupta R, Wikramasinghe P, Bhattacharyya A, Perez FA, Pal S, Davuluri RV. Annotation of gene promoters by integrative data-mining of ChIP-seq Pol-II enrichment data. BMC Bioinformatics 2010, 11(Suppl 1):S65. 10.1186/1471-2105-11-S1-S65, 3009539, 20122241.
7. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476. 10.1038/nature07509, 2593745, 18978772.
8. Singer GA, Wu J, Yan P, Plass C, Huang TH, Davuluri RV. Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genomics 2008, 9:349. 10.1186/1471-2164-9-349, 2527337, 18655706.
9. Barrera LO, Li Z, Smith AD, Arden KC, Cavenee WK, Zhang MQ, Green RD, Ren B. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res 2008, 18:46-59. 2134779, 18042645.
10. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF, Waterman ML. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001, 28:53-57.
11. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011, 16:296-327. 10.2478/s11658-011-0009-9, 21442444.
12. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008, 22:2677-2691. 10.1101/gad.1695308, 2559903, 18805989.
13. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010, 24:549-560. 10.1101/gad.1873910, 2841333, 20194434.
14. Eeckhoute J, Moerman E, Bouckenooghe T, Lukoviak B, Pattou F, Formstecher P, Kerr-Conte J, Vandewalle B, Laine B. Hepatocyte nuclear factor 4 alpha isoforms originated from the P1 promoter are expressed in human pancreatic beta-cells and exhibit stronger transcriptional potentials than P2 promoter-driven isoforms. Endocrinology 2003, 144:1686-1694. 10.1210/en.2002-0024, 12697672.
15. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009, 1796:114-128.
16. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61:2189-2199.
17. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009, 6:454-460. 10.1038/nrurol.2009.125, 19657379.
18. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010, 24:2343-2364. 10.1101/gad.1973010, 2964746, 21041405.
19. Ghigna C, Valacca C, Biamonti G. Alternative splicing and tumor progression. Curr Genomics 2008, 9:556-570. 10.2174/138920208786847971, 2694562, 19516963.
20. Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD, Zhang MQ. Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006, 7:202. 10.1186/1471-2105-7-202, 1458362, 16608523.
21. Moller-Levet CS, Betts GN, Harris AL, Homer JJ, West CM, Miller CJ. Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. PLoS Comput Biol 2009, 5:e1000571. 10.1371/journal.pcbi.1000571, 2773424, 19936049.
22. Clark TA. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 2007, 8:R64. 10.1186/gb-2007-8-4-r64, 1896007, 17456239.
23. Gardina PJ. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325. 10.1186/1471-2164-7-325, 1769375, 17192196.
24. Kwan T, Benovoy D, Dias C, Gurd S, Provencher C, Beaulieu P, Hudson TJ, Sladek R, Majewski J. Genome-wide analysis of transcript isoform variation in humans. Nat Genet 2008, 40:225-231. 10.1038/ng.2007.57, 18193047.
25. McDaniell R, Lee BK, Song L, Liu Z, Boyle AP, Erdos MR, Scott LJ, Morken MA, Kucera KS, Battenhouse A, et al. Heritable individual-specific and allele-specific chromatin signatures in humans. Science 2010, 328:235-239. 10.1126/science.1184655, 2929018, 20299549.
26. Hansen RS, Thomas S, Sandstrom R, Canfield TK, Thurman RE, Weaver M, Dorschner MO, Gartler SM, Stamatoyannopoulos JA. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc Natl Acad Sci USA 2010, 107:139-144. 10.1073/pnas.0912402107, 2806781, 19966280.
27. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al. Integrative analysis of the melanoma transcriptome. Genome Res 2010, 20:413-427. 10.1101/gr.103697.109, 2847744, 20179022.
28. Turro E, Lewin A, Rose A, Dallman MJ, Richardson S. MMBGX: a method for estimating expression at the isoform level and detecting differential splicing using whole-transcript Affymetrix arrays. Nucleic Acids Res 2010, 38:e4. 10.1093/nar/gkp853, 2800219, 19854940.
29. Yates T, Okoniewski MJ, Miller CJ. X:Map: annotation and visualization of genome structure for Affymetrix exon array analysis. Nucleic Acids Res 2008, 36:D780-786. 2238884, 17932061.
30. Cleveland WS, Grosse E, Shyu WM. Local regression models 1992, Wadsworth & Brooks/Cole.
31. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. Journal of the American Statistical Association 1979, 74:829-836.
32. Gordon ADSE. Classification 1999, London: Chapman and Hall/CRC.
33. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 2003, 52:91-118.
34. Smyth GK, Yang YH, Speed T. Statistical issues in cDNA microarray data analysis. Methods Mol Biol 2003, 224:111-136.
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
36. http://www.ingenuity.com/
37. R Development Core Team R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Book R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing 2010, (Editor ed.^eds.). City, R Development Core Team.
38. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26:1572-1573. 10.1093/bioinformatics/btq170, 2881355, 20427518.
39. Rousseeuw PJ. Silhouettes - a Graphical Aid to the Interpretation and Validation of Cluster-Analysis. J Comput Appl Math 1987, 20:53-65.
40. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, Brocker EB, Becker JC. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007, 13:6344-6350. 10.1158/1078-0432.CCR-06-2682, 17975146.
41. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009, 33:237-247. 10.1016/j.molcel.2008.12.026, 2715556, 19187764.
42. Brown JH, Senthil Kumar VS, O'Neall-Hennessey E, Reshetnikova L, Robinson H, Nguyen-McCarty M, Szent-Gyorgyi AG, Cohen C. Visualizing key hinges and a potential major source of compliance in the lever arm of myosin. Proc Natl Acad Sci USA 2010,
43. Pscherer A, Dorflinger U, Kirfel J, Gawlas K, Ruschoff J, Buettner R, Schule R. The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J 1996, 15:6680-6690. 452492, 8978694.
44. Hata S, Emi Y, Iyanagi T, Osumi T. cDNA cloning of a putative G protein-coupled receptor from brain. Biochim Biophys Acta 1995, 1261:121-125. 10.1016/0167-4781(95)00002-X, 7893747.
45. Luska G, Huchzermeyer H, Seifert E, Stender HS. [The radiological diagnosis of non-calculous biliary duct obstruction (author's transl)]. Rofo 1977, 126:117-122. 10.1055/s-0029-1230546, 138635.
46. Gavin BJ, McMahon JA, McMahon AP. Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse development. Genes Dev 1990, 4:2319-2332. 10.1101/gad.4.12b.2319, 2279700.
47. Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T, Jung A. LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med 2010, 8:123. 10.1186/1479-5876-8-123, 2996347, 21092222.
48. Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP. Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int 2009, 55:307-317. 10.1016/j.neuint.2009.03.016, 19576519.
49. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005, 437:281-285. 10.1038/nature03914, 16007074.
50. Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol 2010, 99:155-163. 10.1007/s11060-010-0297-3, 2954435, 20607350.
51. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344. 10.1126/science.1193494, 21127244.
52. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8:1461-1470. 10.1586/14737140.8.9.1461, 18759697.
53. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009, 15:406-420. 10.1097/PPO.0b013e3181bd0445, 19826361.